Effects of different combinations of chemotherapy drugs on untreated mantle cell lymphoma

What we are studying

In step 1, to find out what effects, good and bad, the addition of bortezomib to rituximab plus bendamustine has on study participants and their lymphoma compared to rituximab plus bendamustine alone. In step 2, to find out what effects, good and bad, continuing treatment after step 1 with lenalidomide plus rituximab has on study participants and their lymphoma compared to continuing treatment with rituximab alone.

Who we are studying

  • Men and Women
  • Races:
    • White
    • African American
    • Asian
    • American Indian or Alaska Native
    • Native Hawaiian or Pacific Islander
    • Other
  • All Ethnicities
  • Ages 18 - 80

Eligibility Criteria

  • Untreated mantle cell lymphoma

What is involved

  • Study participants will be randomized to 1 of 4 chemotherapy groups.

Compensation

None

Contact Information

Study Coordinator
Scarlett Hutchens
Email
snhutche@wakehealth.edu
Phone
336-713-6915

Disclaimer: The information on this website is for general informational purposes only and SHOULD NOT be relied upon as a substitute for sound professional medical advice, evaluation or care from your physician or other qualified health care provider.